Finance

Lists
A1SN34:BVMF
Ascendis Pharma A/S Bdr
R$77,28
0,00%
(0,00) 1D
23 Sep., 14:47:37 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1SN34...
Mkt. cap
14,96 mjd
Avg. vol.
61,00
Volume
0,00
52-wk high
R$94,05
52-wk low
R$70,00
Shares outstanding
62,38 m
No. of employees
1 k
Mkt. cap
14,96 mjd
Avg. vol.
61,00
Volume
0,00
52-wk high
R$94,05
52-wk low
R$70,00
Shares outstanding
62,38 m
No. of employees
1 k
News stories
From web sources and news partners
About Ascendis Pharma A/S Bdr
CEO-
Employees1,19 k
Founded2006
Headquarters-
Sector-
Websiteascendispharma.com
Last report
13 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
€0,90 / €0,77
+17,39%beat
Revenue / Est. (EUR)
339,28 m / 329,90 m
+2,84%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
213,63 m
247,50 m
246,60 m
339,28 m
Cost of goods sold
22,35 m
23,60 m
17,52 m
27,66 m
Cost of revenue
22,35 m
23,60 m
17,52 m
27,66 m
Research and development expenses
66,88 m
82,20 m
59,04 m
75,89 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
113,40 m
139,31 m
145,23 m
173,34 m
Operating expense
180,28 m
221,51 m
204,27 m
91,16 m
Total operating expenses
202,64 m
245,11 m
221,79 m
118,82 m
Operating income
11,00 m
2,39 m
24,81 m
220,46 m
Other non operating income
-
-105,57 m
-
-
EBT including unusual items
-57,37 m
-26,70 m
-48,18 m
230,09 m
EBT excluding unusual items
-57,37 m
-34,21 m
-48,18 m
230,09 m
Income tax expense
3,62 m
6,86 m
-677,52 m
23,12 m
Effective tax rate
-6,30%
-25,68%
1 406,31%
10,05%
Other operating expenses
-
-
-
-158,07 m
Net income
-60,99 m
-33,56 m
629,34 m
206,97 m
Net profit margin
-28,55%
-13,56%
255,21%
61,00%
Earnings per share
-1,00
-0,55
0,27
0,90
Interest and investment income
6,04 m
64,06 m
4,52 m
19,96 m
Interest expense
-66,90 m
-74,65 m
-67,26 m
-14,17 m
Net interest expenses
-60,87 m
-10,59 m
-62,74 m
5,79 m
Depreciation and amortization charges
-
-
-
-
EBITDA
15,02 m
3,60 m
29,03 m
225,03 m
Gain or loss from assets sale
-
-
-
21,00 k
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme